Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen-Reference-Cited by-同舟云学术

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen

Published:2018-12 Issue:3 Volume:48 Page:553-557
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Cappelli Laura C.^ORCID,Brahmer Julie R.^ORCID,Forde Patrick M.,Le Dung T.,Lipson Evan J.,Naidoo Jarushka^ORCID,Zheng Lei^ORCID,Bingham Clifton O.,Shah Ami A.

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference18 articles.

1. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

2. Management of immune-related adverse events and kinetics of response with ipilimumab;Weber;J Clin Oncol,2012

3. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity;Calabrese;RMD Open,2017

4. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab;Cappelli;Ann Rheum Dis,2017

5. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4;Goldstein;Arthritis Rheumatol,2014

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors;World Journal of Clinical Oncology;2024-08-24

2. Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study;Rheumatology;2024-06-18

3. For the Long Haul: Management of Long-Term Survivors after Melanoma Systemic Therapy;Current Oncology Reports;2024-05-23

4. The Current and Future of Biomarkers of Immune Related Adverse Events;Rheumatic Disease Clinics of North America;2024-05

5. Immune Checkpoint Inhibitor-induced Inflammatory Arthritis;Rheumatic Disease Clinics of North America;2024-05